Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing of rationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drugs to treat autoimmune and inflammatory diseases easily. It was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Vedanta Biosciences is dedicated to advancing human health by harnessing the power of the microbiome, the diverse community of microorganisms that live within our bodies. Their core mission is to develop a new class of therapies based on rationally designed consortia of bacteria, aiming to treat a wide range of diseases and improve overall health. By leveraging cutting-edge research and innovative technology, Vedanta Biosciences strives to create a paradigm shift in medicine, transforming the way we approach healthcare and fostering a deeper understanding of the intricate relationship between humans and their microbiomes.

• Science-driven: Vedanta Biosciences is dedicated to advancing the field of microbiome research through rigorous scientific inquiry and innovation.
• Collaboration: Vedanta Biosciences fosters a collaborative environment that values diverse perspectives and encourages teamwork to achieve shared goals.
• Patient-focused: Vedanta Biosciences is committed to improving patient health by developing microbiome-based therapies that address unmet medical needs.
• Integrity: Vedanta Biosciences operates with the highest ethical standards, prioritizing transparency, honesty, and accountability in all aspects of its work.